Anti-FCGR4 Antibody, Rabbit Polyclonal

MBS8110831-01mL

Anti-FCGR4 Antibody, Rabbit Polyclonal

567.5 €

MBS8110831-5x01mL

Anti-FCGR4 Antibody, Rabbit Polyclonal

1715 €

MBS8110832-01mL

Anti-FCGR4 Antibody, Rabbit Polyclonal

618.5 €

101225-1

Anti-FcGR3A (CD16A) IgG Antibody, Biotin-Labeled

This anti-FcGR3A (CD16A) antibody is a purified, biotinylated, recombinant human monoclonal antibody which recognizes the human FcGR3A/CD16A protein. Fc Gamma Receptor IIIa (FcGRIIIA; FcγRIIIA), also known as CD16a, is a low/intermediate affinity receptor for polyvalent immune-complexed IgG. It is involved in phagocytosis, antibody-dependent cytotoxicity, and clearance of immune complexes.  FcGR3A/CD16A plays a role in the activation of natural killer (NK) cells. Clinically, it serves as a marker of certain immune cells such as neutrophils. CD16 expression has been observed at the surface of T cells in patients with chronic viral infections (such as COVID-19). It is considered a potential therapeutic target to potentiate the efficacy of therapeutic antibodies used to treat solid tumors, or as direct target in hematopoietic cancers._x000D_This antibody has been tested for specific binding to purified human FcGR3A/CD16A (BPS Bioscience #79013) in an ELISA binding assay with colorimetric detection. It does not cross-react with purified human FcGR2B/CD16B.

525 €

101225-2

Anti-FcGR3A (CD16A) IgG Antibody, Biotin-Labeled

This anti-FcGR3A (CD16A) antibody is a purified, biotinylated, recombinant human monoclonal antibody which recognizes the human FcGR3A/CD16A protein. Fc Gamma Receptor IIIa (FcGRIIIA; FcγRIIIA), also known as CD16a, is a low/intermediate affinity receptor for polyvalent immune-complexed IgG. It is involved in phagocytosis, antibody-dependent cytotoxicity, and clearance of immune complexes.  FcGR3A/CD16A plays a role in the activation of natural killer (NK) cells. Clinically, it serves as a marker of certain immune cells such as neutrophils. CD16 expression has been observed at the surface of T cells in patients with chronic viral infections (such as COVID-19). It is considered a potential therapeutic target to potentiate the efficacy of therapeutic antibodies used to treat solid tumors, or as direct target in hematopoietic cancers._x000D_This antibody has been tested for specific binding to purified human FcGR3A/CD16A (BPS Bioscience #79013) in an ELISA binding assay with colorimetric detection. It does not cross-react with purified human FcGR2B/CD16B.

712.5 €

TA500651

Anti-FCGR2A (CD32) mouse monoclonal antibody, clone OTI16E7 (formerly 16E7)

Ask for quotation